Navigation Links
U.S. NCI Starts Enrolment in Phase 2 Systemic Melanoma Clinical Trial with REOLYSIN(R)
Date:8/12/2008

CALGARY, Aug. 12 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that the U.S. National Cancer Institute (NCI), part of the National Institutes of Health, has started enrolment in a Phase 2 clinical trial for patients with metastatic melanoma using systemic administration of REOLYSIN(R), Oncolytics' proprietary formulation of the human reovirus. The trial is being carried out by the Mayo Phase 2 Consortium under the NCI's Clinical Trials Agreement with Oncolytics, while Oncolytics will provide clinical supplies of REOLYSIN(R). The Principal Investigator is Dr. Evanthia Galanis of the Mayo Clinic Cancer Center.

The primary objectives of the study are to assess the antitumour effects of REOLYSIN(R) in patients with metastatic malignant melanoma, as well as the safety profile of REOLYSIN(R). Secondary objectives include assessment of progression free survival and overall survival.

Patients will receive systemic administration of REOLYSIN(R) at a dose of 3x10(10) TCID(50) per day on days 1-5 of each 28 day cycle, and patients may receive up to 12 cycles of treatment. The trial is expected to enroll up to 47 patients with metastatic melanoma.

Approximately 60,000 people are diagnosed with melanoma in the U.S. every year.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit http://www.oncolyticsbiotech.com

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the Company's expectations related to the U.S. NCI Phase 2 systemic administration clinical trial for patients with metastatic melanoma, and the Company's belief as to the potential of REOLYSIN(R) as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN(R) as a cancer treatment, the tolerability of REOLYSIN(R) outside a controlled test, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN(R), uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements.


'/>"/>
SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. BN ImmunoTherapeutics Starts Clinical Trials With Prostate Cancer Vaccine
2. Impliant Restarts Pivotal Clinical Trial for Patented TOPS(TM) Spine System
3. VIDEO: Femara(R) helps protect against return of breast cancer even when treatment starts several years after completing tamoxifen therapy
4. New Company Starts, Bridging the Development Gap in the Discovery of Cancer Drugs
5. ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III)
6. Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus
7. Neurobiological Technologies Reaches Patient Enrollment Target For Interim Analysis of Viprinex(TM) Phase 3 Stroke Trials
8. Cell Therapeutics Announces that the European Organization for Research and Treatment of Cancer Completes Enrollment in Phase II Clinical Trial of Brostallicin as First Line Therapy for Advanced or Metastatic Soft Tissue Sarcoma
9. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
10. Innocoll Announces Dosing of Last Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-Operative Pain
11. Ardea Biosciences Presents Phase 2a Antiviral Activity Data for Lead HIV Candidate, RDEA806 at XVII International AIDS Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... Dutch surgeons have launched a ground-breaking medical app to help doctors ... a global scale. Medical professionals from Europe , ... the US have already signed up for the app, which combines ... environment. Education  "Imagine a doctor for Medicines ... at Harvard to treat a bomb victim via live streaming - ...
(Date:5/23/2016)... May 23, 2016 According ... Equipment Market by Product (Wheelchair, Scooters, Medical Beds, ... Care, Critical Care, Wound), Accessories (Lifting, Transfer) & ... 2021", published by MarketsandMarkets, the patient handling equipment ... by 2021 at a CAGR of 10.5% during ...
(Date:5/23/2016)... --Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today the start ... hands-on learning experience is a 12-week summer program, May ... and Internship programs bring participants to ... are provided optional housing free of charge through Diplomat ... Riverfront Residence Hall to foster communication and collaboration among ...
Breaking Medicine Technology:
(Date:5/26/2016)... ... ... effort to provide hair restoration information to the widest possible audience, Dr. Parsa Mohebi is ... the app. Dr. Mohebi, the founder of Parsa Mohebi Hair Restoration, is making all of ... Mohebi says, “The positive response to the Snapchat videos we started last month has been ...
(Date:5/26/2016)... ... May 26, 2016 , ... Eating Recovery ... disorders, is opening a brand new child and adolescent residential treatment center on ... families with even more specialized eating disorder treatment and access to life-saving care. ...
(Date:5/26/2016)... ... May 26, 2016 , ... Nike Yoga Camps at ... daily practices, arts & crafts, discussions, and games all geared towards enhancing your ... have combined backgrounds in kids’ yoga, collegiate sport yoga instruction, and global yoga ...
(Date:5/26/2016)... ... 26, 2016 , ... Eugene Batelli, D.P.M., F.A.C.F.A.S, is celebrating ... accolades and stellar patient reviews, Dr. Batelli continues to be recognized for his ... is a highly trained Podiatric Surgeon who specializes in treating athletes and their ...
(Date:5/26/2016)... ... May 26, 2016 , ... OncLive® , a ... Cancer Institute-designated University of Virginia (UVA) Cancer Center to its quickly ... and marketing teams will publicize and promote public awareness of UVA Cancer Center’s ...
Breaking Medicine News(10 mins):